Their lead product, OncoVEXGM-CSF, is an oncolytic vaccine that replicates and spreads within solid tumors, killing cancer cells while leaving healthy cells unharmed. It has been tested in over 110 patients with a range of solid tumors and has shown both direct cell killing and systemic immune-mediated mechanisms of action. BioVex was acquired by Amgen in 2011 and is also developing ImmunoVEXHSV2, a vaccine for genital herpes.